Last edition
News about "Major Adverse Cardiovascular Events (MACE) "
Novo Nordisk Provides Phase 3 ZEUS Trial Update
Novo Nordisk shared an update on the phase 3 ZEUS trial evaluating patients with ASCVD, CKD and inflammation enrolled in a placebo-controlled study.
Major Adverse Cardiovascular Events (MACE) | 03/08/2026 | By News Bureau | 255
Wegovy (Semaglutide 2.4 mg) reduced risk of heart attack, stroke, or death by 57 percent when compared to Tirzepatide, and 29 percent across all patients, showing heart-protective benefits unique to the Semaglutide molecule.
Major Adverse Cardiovascular Events (MACE) | 19/09/2025 | By Dineshwori | 285
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy